Septic Shock News and Research

RSS

Structure of key protein in innate immune response

In a report published in the Journal of Biological Chemistry, scientists in Korea announced their elucidation of three-dimensional structure of CD14 and showed how it is perfectly suited to bind to certain bacterial products.

21 Mar 2005

Discovery may provide a new target to treat sepsis

Part of the immune system's pro-inflammatory response to bacterial invasion is to increase nitric oxide levels with an enzyme called inducible nitric oxide synthase.

14 Mar 2005

New way of looking at MicroRNA and how it controls gene expression

A group of scientists at The Scripps Research Institute is reporting a discovery that sheds light on an area of research fundamental to everything from the normal processes that govern the everyday life of human cells to the aberrant mechanisms that underlie many diseases, including cancer and septic shock.

13 Mar 2005

New understanding of the causes for symptoms of sickle cell disease

A new understanding of the causes for symptoms of sickle cell disease, a condition affecting one in every 600 African-Americans, has resulted from a study by researchers at Duke University Medical Center and Howard Hughes Medical Institute (HHMI). Their findings may lead to a new, more direct method for treating the disease, they said.

31 Jan 2005

Dane County patient dumping case unloads costs on consumers

The Wisconsin Hospital Association expressed disappointment with the Wisconsin Supreme Court’s decision yesterday that allows Dane County and other counties to impose yet another hidden tax on health care consumers.

8 Dec 2004

Potential new drug for the treatment of sickle cell disease

The results were published in the June 2004 issue of The British Journal of Haematology (BJH). MX-1520 is a prodrug of vanillin, a very popular food additive generally regarded as safe (GRAS) by the FDA.

13 Sep 2004

British company to launch "super bug tester" into UK hospitals

MRSA is the first test to be developed from Acolyte’s BacLite® testing platform. BacLite reduces the time for identifying both the type of bacteria and, more importantly, the antibiotic sensitivity of the bacteria from the current 3-4 day standard to just 2-5 hours. This time advantage will mean clinicians will be able to treat, much more effectively, serious bacterial infections and prevent potentially fatal complications, such as sepsis and septic shock, from developing.

24 Mar 2004